GlassScriptPhysician profile
Gregory J Crane
NPI 1225299126
$1,598.55
in general payments reported to CMS, 2019-2025
14 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2024: $271 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Delcath Systems | $748.48 | 2024-2025 | Hepzato Kit |
| Abbvie INC. | $176.27 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $152.61 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $150.92 | 2025 | Enhertu, Calquence |
| Gilead Sciences, INC. | $58.15 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $54.35 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $51.64 | 2024-2025 | |
| Incyte Corporation | $38.59 | 2025 | Monjuvi, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $37.52 | 2025 | Opdivo |
| Genentech USA, INC. | $36.83 | 2025 | Itovebi, Polivy |
| Pfizer INC. | $36.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.65 | 2025 | Alunbrig |
| Genzyme Corporation | $18.45 | 2025 | |
| Eisai INC. | $14.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.